APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spinal Muscular Atrophy Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Spinal Muscular Atrophy Medicine Market Analysis and Forecast 2026-2032

26 December 2025203 pages

Choose your research edition.

Industry ResearchSpinal Muscular Atrophy Medicine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal Muscular Atrophy Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Spinal Muscular Atrophy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal Muscular Atrophy Medicine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal Muscular Atrophy Medicine Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Spinal Muscular Atrophy Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Spinal Muscular Atrophy Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Spinal Muscular Atrophy Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Spinal Muscular Atrophy Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Spinal Muscular Atrophy Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Spinal Muscular Atrophy Medicine include Novartis AG, Astellas Pharma Inc., WAVE Life Sciences Ltd., Vybion, Inc., Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neurotune AG, Neurodyn Inc. and Longevity Biotech, Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Spinal Muscular Atrophy Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Spinal Muscular Atrophy Medicine, also provides the sales of main regions and countries. Of the upcoming market potential for Spinal Muscular Atrophy Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Spinal Muscular Atrophy Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Spinal Muscular Atrophy Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Spinal Muscular Atrophy Medicine sales, projected growth trends, production technology, application and end-user industry.

Spinal Muscular Atrophy Medicine Segment by Company

Novartis AG

Astellas Pharma Inc.

WAVE Life Sciences Ltd.

Vybion, Inc.

Voyager Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Neurotune AG

Neurodyn Inc.

Longevity Biotech, Inc

Ionis Pharmaceuticals, Inc.

GMP-Orphan SAS

Genzyme Corporation

Genethon

F. Hoffmann-La Roche Ltd.

Cytokinetics, Inc. 24

Bioblast Pharma Ltd.

AveXis, Inc.

Spinal Muscular Atrophy Medicine Segment by Type

LMI-070

ND-602

NT-1654

NXD-30001

Nusinersen

Others

Spinal Muscular Atrophy Medicine Segment by Application

Hospital

Clinic

Others

Spinal Muscular Atrophy Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal Muscular Atrophy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal Muscular Atrophy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal Muscular Atrophy Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Spinal Muscular Atrophy Medicine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Spinal Muscular Atrophy Medicine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. LMI-070 Major Manufacturers Table 3. ND-602 Major Manufacturers Table 4. NT-1654 Major Manufacturers Table 5. NXD-30001 Major Manufacturers Table 6. Nusinersen Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Manufacturers Table 10. Clinic Major Manufacturers Table 11. Others Major Manufacturers Table 12. Spinal Muscular Atrophy Medicine Industry Trends Table 13. Spinal Muscular Atrophy Medicine Industry Drivers Table 14. Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges Table 15. Spinal Muscular Atrophy Medicine Industry Restraints Table 16. Global Spinal Muscular Atrophy Medicine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Spinal Muscular Atrophy Medicine Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2026) Table 20. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2027-2032) Table 21. Global Spinal Muscular Atrophy Medicine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 22. Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (W Units) Table 23. Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032) & (W Units) Table 24. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026) Table 25. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2027-2032) Table 26. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2021-2026) Table 30. Global Spinal Muscular Atrophy Medicine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Spinal Muscular Atrophy Medicine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Spinal Muscular Atrophy Medicine Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Spinal Muscular Atrophy Medicine Manufacturers, Product Type & Application Table 34. Global Spinal Muscular Atrophy Medicine Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Spinal Muscular Atrophy Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Spinal Muscular Atrophy Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026) Table 41. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2027-2032) Table 42. Global Spinal Muscular Atrophy Medicine Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 43. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 44. Global Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 45. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026) Table 46. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2027-2032) Table 47. Global Spinal Muscular Atrophy Medicine Price by Type (2021-2026) & (US$/Unit) Table 48. Global Spinal Muscular Atrophy Medicine Price by Type (2027-2032) & (US$/Unit) Table 49. Global Spinal Muscular Atrophy Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2026) Table 53. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2027-2032) Table 54. Global Spinal Muscular Atrophy Medicine Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 55. Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 56. Global Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 57. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026) Table 58. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2027-2032) Table 59. Global Spinal Muscular Atrophy Medicine Price by Application (2021-2026) & (US$/Unit) Table 60. Global Spinal Muscular Atrophy Medicine Price by Application (2027-2032) & (US$/Unit) Table 61. Novartis AG Company Information Table 62. Novartis AG Business Overview Table 63. Novartis AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio Table 65. Novartis AG Recent Development Table 66. Astellas Pharma Inc. Company Information Table 67. Astellas Pharma Inc. Business Overview Table 68. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 70. Astellas Pharma Inc. Recent Development Table 71. WAVE Life Sciences Ltd. Company Information Table 72. WAVE Life Sciences Ltd. Business Overview Table 73. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 75. WAVE Life Sciences Ltd. Recent Development Table 76. Vybion, Inc. Company Information Table 77. Vybion, Inc. Business Overview Table 78. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 80. Vybion, Inc. Recent Development Table 81. Voyager Therapeutics, Inc. Company Information Table 82. Voyager Therapeutics, Inc. Business Overview Table 83. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 85. Voyager Therapeutics, Inc. Recent Development Table 86. Sarepta Therapeutics, Inc. Company Information Table 87. Sarepta Therapeutics, Inc. Business Overview Table 88. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 90. Sarepta Therapeutics, Inc. Recent Development Table 91. Neurotune AG Company Information Table 92. Neurotune AG Business Overview Table 93. Neurotune AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio Table 95. Neurotune AG Recent Development Table 96. Neurodyn Inc. Company Information Table 97. Neurodyn Inc. Business Overview Table 98. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 100. Neurodyn Inc. Recent Development Table 101. Longevity Biotech, Inc Company Information Table 102. Longevity Biotech, Inc Business Overview Table 103. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio Table 105. Longevity Biotech, Inc Recent Development Table 106. Ionis Pharmaceuticals, Inc. Company Information Table 107. Ionis Pharmaceuticals, Inc. Business Overview Table 108. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 110. Ionis Pharmaceuticals, Inc. Recent Development Table 111. GMP-Orphan SAS Company Information Table 112. GMP-Orphan SAS Business Overview Table 113. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio Table 115. GMP-Orphan SAS Recent Development Table 116. Genzyme Corporation Company Information Table 117. Genzyme Corporation Business Overview Table 118. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio Table 120. Genzyme Corporation Recent Development Table 121. Genethon Company Information Table 122. Genethon Business Overview Table 123. Genethon Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Genethon Spinal Muscular Atrophy Medicine Product Portfolio Table 125. Genethon Recent Development Table 126. F. Hoffmann-La Roche Ltd. Company Information Table 127. F. Hoffmann-La Roche Ltd. Business Overview Table 128. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 130. F. Hoffmann-La Roche Ltd. Recent Development Table 131. Cytokinetics, Inc. 24 Company Information Table 132. Cytokinetics, Inc. 24 Business Overview Table 133. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio Table 135. Cytokinetics, Inc. 24 Recent Development Table 136. Bioblast Pharma Ltd. Company Information Table 137. Bioblast Pharma Ltd. Business Overview Table 138. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 140. Bioblast Pharma Ltd. Recent Development Table 141. AveXis, Inc. Company Information Table 142. AveXis, Inc. Business Overview Table 143. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 145. AveXis, Inc. Recent Development Table 146. North America Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 147. North America Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 148. North America Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 149. North America Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 150. North America Spinal Muscular Atrophy Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 151. North America Spinal Muscular Atrophy Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 152. North America Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 153. North America Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 154. North America Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 155. North America Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 156. North America Spinal Muscular Atrophy Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 157. North America Spinal Muscular Atrophy Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 158. North America Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. North America Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. North America Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. North America Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 162. North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 163. North America Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 164. North America Spinal Muscular Atrophy Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 165. North America Spinal Muscular Atrophy Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 166. United States Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 167. Canada Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 168. Europe Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 169. Europe Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 170. Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 171. Europe Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 172. Europe Spinal Muscular Atrophy Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 173. Europe Spinal Muscular Atrophy Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 174. Europe Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 175. Europe Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 176. Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 177. Europe Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 178. Europe Spinal Muscular Atrophy Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 179. Europe Spinal Muscular Atrophy Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 180. Europe Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. Europe Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 182. Europe Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 183. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 184. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 185. Europe Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 186. Europe Spinal Muscular Atrophy Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 187. Europe Spinal Muscular Atrophy Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 188. Germany Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 189. France Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 190. U.K. Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 191. Italy Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 192. Russia Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 193. Spain Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 194. Netherlands Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 195. Switzerland Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 196. Sweden Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 197. Poland Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 198. China Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 199. China Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 200. China Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 201. China Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 202. China Spinal Muscular Atrophy Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 203. China Spinal Muscular Atrophy Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 204. China Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 205. China Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 206. China Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 207. China Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 208. China Spinal Muscular Atrophy Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 209. China Spinal Muscular Atrophy Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 210. Asia Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 211. Asia Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 212. Asia Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 213. Asia Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 214. Asia Spinal Muscular Atrophy Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 215. Asia Spinal Muscular Atrophy Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 216. Asia Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 217. Asia Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 218. Asia Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 219. Asia Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 220. Asia Spinal Muscular Atrophy Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 221. Asia Spinal Muscular Atrophy Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 222. Asia Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 223. Asia Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 224. Asia Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 225. Asia Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 226. Asia Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 227. Asia Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 228. Asia Spinal Muscular Atrophy Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 229. Asia Spinal Muscular Atrophy Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 230. Japan Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 231. South Korea Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 232. India Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 233. Australia Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 234. Taiwan Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 235. Southeast Asia Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 236. SAMEA Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 237. SAMEA Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 238. SAMEA Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 239. SAMEA Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 240. SAMEA Spinal Muscular Atrophy Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 241. SAMEA Spinal Muscular Atrophy Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 242. SAMEA Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 243. SAMEA Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 244. SAMEA Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 245. SAMEA Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 246. SAMEA Spinal Muscular Atrophy Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 247. SAMEA Spinal Muscular Atrophy Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 248. SAMEA Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 249. SAMEA Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 250. SAMEA Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 251. SAMEA Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 252. SAMEA Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 253. SAMEA Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 254. SAMEA Spinal Muscular Atrophy Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 255. SAMEA Spinal Muscular Atrophy Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 256. Brazil Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 257. Argentina Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 258. Chile Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 259. Colombia Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 260. Peru Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 261. Saudi Arabia Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 262. Israel Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 263. UAE Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 264. Turkey Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 265. Iran Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 266. Egypt Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Table 267. Key Raw Materials Table 268. Raw Materials Key Suppliers Table 269. Spinal Muscular Atrophy Medicine Distributors List Table 270. Spinal Muscular Atrophy Medicine Customers List Table 271. Research Programs/Design for This Report Table 272. Authors List of This Report Table 273. Secondary Sources Table 274. Primary Sources List of Figures Figure 1. Spinal Muscular Atrophy Medicine Image Figure 2. Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spinal Muscular Atrophy Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. LMI-070 Image Figure 5. ND-602 Image Figure 6. NT-1654 Image Figure 7. NXD-30001 Image Figure 8. Nusinersen Image Figure 9. Others Image Figure 10. Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Spinal Muscular Atrophy Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Figure 17. Global Spinal Muscular Atrophy Medicine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2032) Figure 20. Global Spinal Muscular Atrophy Medicine Sales (2021-2032) & (W Units) Figure 21. Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 22. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Spinal Muscular Atrophy Medicine Sales YoY (2021-2032) & (W Units) Figure 24. Europe Spinal Muscular Atrophy Medicine Sales YoY (2021-2032) & (W Units) Figure 25. China Spinal Muscular Atrophy Medicine Sales YoY (2021-2032) & (W Units) Figure 26. Asia (Excluding China) Spinal Muscular Atrophy Medicine Sales YoY (2021-2032) & (W Units) Figure 27. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales YoY (2021-2032) & (W Units) Figure 28. Global Spinal Muscular Atrophy Medicine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Spinal Muscular Atrophy Medicine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032) Figure 34. Global Spinal Muscular Atrophy Medicine Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032) Figure 37. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032) Figure 40. Global Spinal Muscular Atrophy Medicine Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 41. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032) Figure 43. North America Spinal Muscular Atrophy Medicine Revenue Share by Type (2021-2032) Figure 44. North America Spinal Muscular Atrophy Medicine Sales Share by Type (2021-2032) Figure 45. North America Spinal Muscular Atrophy Medicine Revenue Share by Application (2021-2032) Figure 46. North America Spinal Muscular Atrophy Medicine Sales Share by Application (2021-2032) Figure 47. North America Spinal Muscular Atrophy Medicine Revenue Share by Country (2021-2032) Figure 48. North America Spinal Muscular Atrophy Medicine Sales Share by Country (2021-2032) Figure 49. Europe Spinal Muscular Atrophy Medicine Revenue Share by Type (2021-2032) Figure 50. Europe Spinal Muscular Atrophy Medicine Sales Share by Type (2021-2032) Figure 51. Europe Spinal Muscular Atrophy Medicine Revenue Share by Application (2021-2032) Figure 52. Europe Spinal Muscular Atrophy Medicine Sales Share by Application (2021-2032) Figure 53. Europe Spinal Muscular Atrophy Medicine Revenue Share by Country (2021-2032) Figure 54. Europe Spinal Muscular Atrophy Medicine Sales Share by Country (2021-2032) Figure 55. China Spinal Muscular Atrophy Medicine Revenue Share by Type (2021-2032) Figure 56. China Spinal Muscular Atrophy Medicine Sales Share by Type (2021-2032) Figure 57. China Spinal Muscular Atrophy Medicine Revenue Share by Application (2021-2032) Figure 58. China Spinal Muscular Atrophy Medicine Sales Share by Application (2021-2032) Figure 59. Asia Spinal Muscular Atrophy Medicine Revenue Share by Type (2021-2032) Figure 60. Asia Spinal Muscular Atrophy Medicine Sales Share by Type (2021-2032) Figure 61. Asia Spinal Muscular Atrophy Medicine Revenue Share by Application (2021-2032) Figure 62. Asia Spinal Muscular Atrophy Medicine Sales Share by Application (2021-2032) Figure 63. Asia Spinal Muscular Atrophy Medicine Revenue Share by Country (2021-2032) Figure 64. Asia Spinal Muscular Atrophy Medicine Sales Share by Country (2021-2032) Figure 65. SAMEA Spinal Muscular Atrophy Medicine Revenue Share by Type (2021-2032) Figure 66. SAMEA Spinal Muscular Atrophy Medicine Sales Share by Type (2021-2032) Figure 67. SAMEA Spinal Muscular Atrophy Medicine Revenue Share by Application (2021-2032) Figure 68. SAMEA Spinal Muscular Atrophy Medicine Sales Share by Application (2021-2032) Figure 69. SAMEA Spinal Muscular Atrophy Medicine Revenue Share by Country (2021-2032) Figure 70. SAMEA Spinal Muscular Atrophy Medicine Sales Share by Country (2021-2032) Figure 71. Spinal Muscular Atrophy Medicine Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Spinal Muscular Atrophy Medicine Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • LMI-070
  • ND-602
  • NT-1654
  • NXD-30001
  • Nusinersen
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Astellas Pharma Inc.
  • WAVE Life Sciences Ltd.
  • Vybion, Inc.
  • Voyager Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Neurotune AG
  • Neurodyn Inc.
  • Longevity Biotech, Inc
  • Ionis Pharmaceuticals, Inc.
  • GMP-Orphan SAS
  • Genzyme Corporation
  • Genethon
  • F. Hoffmann-La Roche Ltd.
  • Cytokinetics, Inc. 24
  • Bioblast Pharma Ltd.
  • AveXis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Spinal Muscular Atrophy Medicine Market by Type
  3. 1.2.1 Global Spinal Muscular Atrophy Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 LMI-070
  5. 1.2.3 ND-602
  6. 1.2.4 NT-1654
  7. 1.2.5 NXD-30001
  8. 1.2.6 Nusinersen
  9. 1.2.7 Others
  10. 1.3 Spinal Muscular Atrophy Medicine Market by Application
  11. 1.3.1 Global Spinal Muscular Atrophy Medicine Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Spinal Muscular Atrophy Medicine Market Dynamics
  1. 2.1 Spinal Muscular Atrophy Medicine Industry Trends
  2. 2.2 Spinal Muscular Atrophy Medicine Industry Drivers
  3. 2.3 Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges
  4. 2.4 Spinal Muscular Atrophy Medicine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Spinal Muscular Atrophy Medicine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Spinal Muscular Atrophy Medicine Revenue by Region
  3. 3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026)
  5. 3.2.3 Global Spinal Muscular Atrophy Medicine Revenue by Region (2027-2032)
  6. 3.2.4 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Spinal Muscular Atrophy Medicine Sales by Region
  9. 3.4.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026)
  11. 3.4.3 Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032)
  12. 3.4.4 Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers
  2. 4.1.1 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Spinal Muscular Atrophy Medicine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers
  6. 4.2.1 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Spinal Muscular Atrophy Medicine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Spinal Muscular Atrophy Medicine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Spinal Muscular Atrophy Medicine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Spinal Muscular Atrophy Medicine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Spinal Muscular Atrophy Medicine Manufacturers, Product Type & Application
  13. 4.7 Global Spinal Muscular Atrophy Medicine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Spinal Muscular Atrophy Medicine Market CR5 and HHI
  16. 4.8.2 2025 Spinal Muscular Atrophy Medicine Tier 1, Tier 2, and Tier 3
5 Spinal Muscular Atrophy Medicine Market by Type
  1. 5.1 Global Spinal Muscular Atrophy Medicine Revenue by Type
  2. 5.1.1 Global Spinal Muscular Atrophy Medicine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Spinal Muscular Atrophy Medicine Sales by Type
  6. 5.2.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Spinal Muscular Atrophy Medicine Price by Type
6 Spinal Muscular Atrophy Medicine Market by Application
  1. 6.1 Global Spinal Muscular Atrophy Medicine Revenue by Application
  2. 6.1.1 Global Spinal Muscular Atrophy Medicine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Spinal Muscular Atrophy Medicine Sales by Application
  6. 6.2.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Spinal Muscular Atrophy Medicine Price by Application
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Astellas Pharma Inc.
  8. 7.2.1 Astellas Pharma Inc. Company Information
  9. 7.2.2 Astellas Pharma Inc. Business Overview
  10. 7.2.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  12. 7.2.5 Astellas Pharma Inc. Recent Developments
  13. 7.3 WAVE Life Sciences Ltd.
  14. 7.3.1 WAVE Life Sciences Ltd. Company Information
  15. 7.3.2 WAVE Life Sciences Ltd. Business Overview
  16. 7.3.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  18. 7.3.5 WAVE Life Sciences Ltd. Recent Developments
  19. 7.4 Vybion, Inc.
  20. 7.4.1 Vybion, Inc. Company Information
  21. 7.4.2 Vybion, Inc. Business Overview
  22. 7.4.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  24. 7.4.5 Vybion, Inc. Recent Developments
  25. 7.5 Voyager Therapeutics, Inc.
  26. 7.5.1 Voyager Therapeutics, Inc. Company Information
  27. 7.5.2 Voyager Therapeutics, Inc. Business Overview
  28. 7.5.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  30. 7.5.5 Voyager Therapeutics, Inc. Recent Developments
  31. 7.6 Sarepta Therapeutics, Inc.
  32. 7.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 7.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 7.6.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  36. 7.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 7.7 Neurotune AG
  38. 7.7.1 Neurotune AG Company Information
  39. 7.7.2 Neurotune AG Business Overview
  40. 7.7.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
  42. 7.7.5 Neurotune AG Recent Developments
  43. 7.8 Neurodyn Inc.
  44. 7.8.1 Neurodyn Inc. Company Information
  45. 7.8.2 Neurodyn Inc. Business Overview
  46. 7.8.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  48. 7.8.5 Neurodyn Inc. Recent Developments
  49. 7.9 Longevity Biotech, Inc
  50. 7.9.1 Longevity Biotech, Inc Company Information
  51. 7.9.2 Longevity Biotech, Inc Business Overview
  52. 7.9.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
  54. 7.9.5 Longevity Biotech, Inc Recent Developments
  55. 7.10 Ionis Pharmaceuticals, Inc.
  56. 7.10.1 Ionis Pharmaceuticals, Inc. Company Information
  57. 7.10.2 Ionis Pharmaceuticals, Inc. Business Overview
  58. 7.10.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  60. 7.10.5 Ionis Pharmaceuticals, Inc. Recent Developments
  61. 7.11 GMP-Orphan SAS
  62. 7.11.1 GMP-Orphan SAS Company Information
  63. 7.11.2 GMP-Orphan SAS Business Overview
  64. 7.11.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
  66. 7.11.5 GMP-Orphan SAS Recent Developments
  67. 7.12 Genzyme Corporation
  68. 7.12.1 Genzyme Corporation Company Information
  69. 7.12.2 Genzyme Corporation Business Overview
  70. 7.12.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
  72. 7.12.5 Genzyme Corporation Recent Developments
  73. 7.13 Genethon
  74. 7.13.1 Genethon Company Information
  75. 7.13.2 Genethon Business Overview
  76. 7.13.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
  78. 7.13.5 Genethon Recent Developments
  79. 7.14 F. Hoffmann-La Roche Ltd.
  80. 7.14.1 F. Hoffmann-La Roche Ltd. Company Information
  81. 7.14.2 F. Hoffmann-La Roche Ltd. Business Overview
  82. 7.14.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  84. 7.14.5 F. Hoffmann-La Roche Ltd. Recent Developments
  85. 7.15 Cytokinetics, Inc. 24
  86. 7.15.1 Cytokinetics, Inc. 24 Company Information
  87. 7.15.2 Cytokinetics, Inc. 24 Business Overview
  88. 7.15.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
  90. 7.15.5 Cytokinetics, Inc. 24 Recent Developments
  91. 7.16 Bioblast Pharma Ltd.
  92. 7.16.1 Bioblast Pharma Ltd. Company Information
  93. 7.16.2 Bioblast Pharma Ltd. Business Overview
  94. 7.16.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  96. 7.16.5 Bioblast Pharma Ltd. Recent Developments
  97. 7.17 AveXis, Inc.
  98. 7.17.1 AveXis, Inc. Company Information
  99. 7.17.2 AveXis, Inc. Business Overview
  100. 7.17.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  102. 7.17.5 AveXis, Inc. Recent Developments
8 North America
  1. 8.1 North America Spinal Muscular Atrophy Medicine Market Size by Type
  2. 8.1.1 North America Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  3. 8.1.2 North America Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  4. 8.1.3 North America Spinal Muscular Atrophy Medicine Price by Type (2021-2032)
  5. 8.2 North America Spinal Muscular Atrophy Medicine Market Size by Application
  6. 8.2.1 North America Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  7. 8.2.2 North America Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  8. 8.2.3 North America Spinal Muscular Atrophy Medicine Price by Application (2021-2032)
  9. 8.3 North America Spinal Muscular Atrophy Medicine Market Size by Country
  10. 8.3.1 North America Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Spinal Muscular Atrophy Medicine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Spinal Muscular Atrophy Medicine Market Size by Type
  2. 9.1.1 Europe Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  4. 9.1.3 Europe Spinal Muscular Atrophy Medicine Price by Type (2021-2032)
  5. 9.2 Europe Spinal Muscular Atrophy Medicine Market Size by Application
  6. 9.2.1 Europe Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  8. 9.2.3 Europe Spinal Muscular Atrophy Medicine Price by Application (2021-2032)
  9. 9.3 Europe Spinal Muscular Atrophy Medicine Market Size by Country
  10. 9.3.1 Europe Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Spinal Muscular Atrophy Medicine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Spinal Muscular Atrophy Medicine Market Size by Type
  2. 10.1.1 China Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  3. 10.1.2 China Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  4. 10.1.3 China Spinal Muscular Atrophy Medicine Price by Type (2021-2032)
  5. 10.2 China Spinal Muscular Atrophy Medicine Market Size by Application
  6. 10.2.1 China Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  7. 10.2.2 China Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  8. 10.2.3 China Spinal Muscular Atrophy Medicine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Spinal Muscular Atrophy Medicine Market Size by Type
  2. 11.1.1 Asia Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  4. 11.1.3 Asia Spinal Muscular Atrophy Medicine Price by Type (2021-2032)
  5. 11.2 Asia Spinal Muscular Atrophy Medicine Market Size by Application
  6. 11.2.1 Asia Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  8. 11.2.3 Asia Spinal Muscular Atrophy Medicine Price by Application (2021-2032)
  9. 11.3 Asia Spinal Muscular Atrophy Medicine Market Size by Country
  10. 11.3.1 Asia Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Spinal Muscular Atrophy Medicine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Spinal Muscular Atrophy Medicine Market Size by Type
  2. 12.1.1 SAMEA Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Spinal Muscular Atrophy Medicine Price by Type (2021-2032)
  5. 12.2 SAMEA Spinal Muscular Atrophy Medicine Market Size by Application
  6. 12.2.1 SAMEA Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Spinal Muscular Atrophy Medicine Price by Application (2021-2032)
  9. 12.3 SAMEA Spinal Muscular Atrophy Medicine Market Size by Country
  10. 12.3.1 SAMEA Spinal Muscular Atrophy Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Spinal Muscular Atrophy Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Spinal Muscular Atrophy Medicine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Spinal Muscular Atrophy Medicine Value Chain Analysis
  2. 13.1.1 Spinal Muscular Atrophy Medicine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Spinal Muscular Atrophy Medicine Production Mode & Process
  6. 13.2 Spinal Muscular Atrophy Medicine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Spinal Muscular Atrophy Medicine Distributors
  9. 13.2.3 Spinal Muscular Atrophy Medicine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst